Security
Fresenius Med Car Ag Pfd N Vtg Ordinary Shares · FMCQF
FMCQFOTCPreferred stockCurrentCIK 1333141Updated Oct 8, 2026
Name history
Fresenius Medical Care AG & Co. KGaA · through Nov 21, 2023
FMCQF price & chart
Loading TradingView…
OTC:FMCQF on TradingView ↗About the company
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,513 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · EURSource
Source
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | 1,191,267,000Source | 740,870,000Source | 732,458,000Source | 894,325,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossEUR | 1,500,409,000Source | 1,742,257,000Source | 1,751,971,000Source | 1,838,363,000Source |
| DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersEUR | 416,140,000Source | 422,515,000Source | 349,162,000Source | 328,623,000Source |
| GeneralAndAdministrativeExpenseEUR | 2,414,591,000Source | 2,366,287,000Source | 2,388,375,000Source | — |
| GoodwillEUR | 13,571,394,000Source | 15,170,652,000Source | 14,650,008,000Source | 15,791,181,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR | 225,751,000Source | 444,586,000Source | 410,126,000Source | 334,615,000Source |
| InterestPaidClassifiedAsOperatingActivitiesEUR | 359,982,000Source | 381,226,000Source | 394,535,000Source | 350,681,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | 68,155,000Source | 68,099,000Source | 88,217,000Source | 67,663,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | 649,038,000Source | — | — | — |
| PaymentsToAcquireOrRedeemEntitysSharesEUR | 585,285,000Source | — | — | — |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | 16,695,000Source | 14,103,000Source | 16,138,000Source | 36,205,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | 4,668,000Source | 8,544,000Source | 26,366,000Source | 46,348,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseEUR | 3,032,728,000Source | 3,142,819,000Source | 3,196,336,000Source | 3,784,634,000Source |
| Total RevenueEUR | 19,627,602,000Source | 19,335,909,000Source | 19,453,617,000Source | 19,398,017,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.3Source | 0.3Source | 0.3Source | 0.3Source |
| AuditorsRemunerationForTaxServicesEUR | 23,000Source | — | — | 1,204,000Source |
| AverageEffectiveTaxRatenumber | 0.21Source | 0.3Source | 0.29Source | 0.27Source |
| BasicEarningsLossPerShareEUR/shares | 3.36Source | 1.83Source | 1.7Source | 2.3Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossEUR | -27,212,000Source | -72,671,000Source | -122,149,000Source | -41,471,000Source |
| DepreciationAndAmortisationExpenseEUR | 1,463,413,000Source | 1,535,536,000Source | 1,612,737,000Source | 1,718,802,000Source |
| DepreciationRightofuseAssetsEUR | 647,620,000Source | 675,526,000Source | 700,671,000Source | 746,471,000Source |
| DilutedEarningsLossPerShareEUR/shares | 3.36Source | 1.83Source | 1.7Source | 2.3Source |
| EmployeeBenefitsExpenseEUR | 7,651,054,000Source | 7,788,818,000Source | 7,768,210,000Source | 7,939,397,000Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedEUR | 14,249,000Source | 20,104,000Source | 22,188,000Source | 17,421,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedEUR | 65,209,000Source | 53,057,000Source | 59,327,000Source | 52,420,000Source |
| ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilitiesEUR | 2,833,000Source | 6,343,000Source | 10,465,000Source | 13,803,000Source |
| FinanceCostsEUR | 384,409,000Source | 407,044,000Source | 424,640,000Source | 360,139,000Source |
| FinanceIncomeEUR | 69,611,000Source | 71,575,000Source | 88,217,000Source | 67,663,000Source |
| GeneralAndAdministrativeExpenseEUR | 2,414,591,000Source | 2,366,287,000Source | 2,388,375,000Source | — |
| GrossProfitEUR | — | — | — | 5,310,252,000Source |
| ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossEUR | 36,996,000Source | 206,721,000Source | 139,234,000Source | 119,561,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | 320,971,000Source | 316,056,000Source | 300,557,000Source | 324,954,000Source |
| InterestExpenseEUR | 375,216,000Source | 393,322,000Source | 420,900,000Source | 358,995,000Source |
| InterestExpenseOnLeaseLiabilitiesEUR | 143,211,000Source | 148,420,000Source | 148,789,000Source | 151,317,000Source |
| OtherIncomeEUR | 528,099,000Source | 760,118,000Source | 515,247,000Source | — |
| PostemploymentBenefitExpenseDefinedBenefitPlansEUR | 47,138,000Source | 52,402,000Source | 55,582,000Source | 53,782,000Source |
| ProfitLossAttributableToNoncontrollingInterestsEUR | 212,900,000Source | 202,957,000Source | 233,461,000Source | 220,920,000Source |
| ProfitLossAttributableToOwnersOfParentEUR | 978,367,000Source | 537,913,000Source | 498,997,000Source | 673,405,000Source |
| ProfitLossBeforeTaxEUR | 1,512,238,000Source | 1,056,926,000Source | 1,033,015,000Source | 1,219,279,000Source |
| ProfitLossFromOperatingActivitiesEUR | 1,827,036,000Source | 1,392,395,000Source | 1,369,438,000Source | 1,511,755,000Source |
| ResearchAndDevelopmentExpenseEUR | 157,975,000Source | 183,493,000Source | 231,970,000Source | 228,624,000Source |
| RevenueFromInterestEUR | 68,022,000Source | 68,998,000Source | 124,751,000Source | 56,409,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodEUR | 181,368,000Source | 134,875,000Source | 121,785,000Source | 66,559,000Source |
Filing attachments
tm2627207d1_ex99-1.htm · 6-K · 2026-10-07
Exhibit 99.1 Press Release Media contacts Sven Jacobsen T +49 171 2879 127 sven.jacobsen@freseniusmedicalcare.com Ryan Jimenez T +1 781 699 3900 ryan.jimenez@freseniusmedicalcare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2525 domini…
Read attachment ↗tm2626162d1_ex99-1.htm · 6-K · 2026-09-25
Exhibit 99.1 Press Release Media contacts Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Ryan Jimenez T +1 781 699 3900 ryan.jimenez@freseniusmedicalcare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2525 …
Read attachment ↗tm2624187d1_ex99-1.htm · 6-K · 2026-08-27
Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Kirsten Stratton T +1 781 929 8096 kirsten.stratton@freseniusmedicalcare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2525 dominik.heger@freseniusmedicalcare.com www.freseniusmedicalcare.com Fresenius Medical Care Announces Publication of a Multinational Real-World Evidence Study Associating High-Volume Hemodiafiltration with…
Read attachment ↗tm2622055d1_ex99-1.htm · 6-K · 2026-08-03
Exhibit 99.1 Media contact Press Release Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Kirsten Stratton T +1 781 929 8096 kirsten.stratton@freseniusmedicalcare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2525 dominik.heger@freseniusmedicalcare.com Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery Bad Homburg (August 3, 2026) - The Supervisory Board of Fresenius Medic…
Read attachment ↗tm2620437d2_ex99-1.htm · 6-K · 2026-08-03
Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 Christine. Peters@FreseniusMedicalCare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2525 Dominik. Heger@FreseniusMedicalCare.com www.freseniusmedicalcare.com Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda Organic revenue growth1 of 5% with growth in all operating segments Operating income…
Read attachment ↗tm2620437d2_ex99-2.htm · 6-K · 2026-08-03
Exhibit 99.2 Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 page 6 Key metrics page 7 page 8 Outlook 2026 page 9 Disclaimer Copyright by Fresenius Medical Care AG email: ir@freseniusmedicalcare.com phone: +49 6172 609 2525 Revenue development by segment Reconciliation results excl. special items This release contains forward-looking statements that are subject to various risks and uncertainties. Actual resul…
Read attachment ↗